Eylea 114.3 mg/ml solution for injection clinical trials

(22578) An open-label, non-randomized, multi-center, phase 4 pharmacokinetic study to evaluate the systemic exposure after bilateral intravitreal administration of high dose (8 mg) aflibercept in adults with diabetic macular edema or neovascular age-related macular degeneration

This study is looking at how a higher dose of a medicine called Eylea (aflibercept) works in people with wet age-related macular degeneration or diabetic macular oedema. It wants to see how much of the medicine gets into the body after it's injected into both eyes.